Save your place

Sign in to WhoBought

Please try again later.

Invesco's Agilon Health, Inc. (AGL) position

Yes: as of Q1 2026, Invesco holds 41K shares of AGL worth an amount we cannot price (0.0% of the disclosed portfolio). Last quarter the position was opened. First disclosed Q1 2026.
View full portfolio →
Current value
an amount we cannot price
Shares held
41K
% of portfolio
0.0%
Quarter-end price
No quarter-end price available

Average buy price is hidden here because at least one covered purchase quarter has no usable local mean price.

AGL price vs Invesco's position

Dates
$115$120$125$130← Earlier —1 purchase
Average closing price · filing quarter
Price range · filing quarter

Every quarterly change

Quarter Action Shares change Est. value change Δ Own Shares held Filing date
Q1 2026 New +41K 41K May 12, 2026
Data through Q1 2026 · filed May 12, 2026
1 grouped rows from 1 quarters

More Invesco positions

Common questions

Does Invesco own AGL?

Yes. As of Q1 2026, Invesco disclosed 41K shares of AGL, worth an amount we cannot price. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

When did Invesco buy AGL?

Invesco first disclosed a AGL position in Q1 2026; every quarterly buy and sell since is in the table above. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

Did Invesco sell AGL?

The quarter-by-quarter table above shows each sale and reduction Invesco disclosed in AGL. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

How many shares of AGL does Invesco own?

Invesco disclosed 41K shares of AGL as of Q1 2026. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

What price did Invesco pay for AGL?

Invesco began building the AGL position before our 13F history starts, so an exact average buy price cannot be estimated without understating it. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.

How are the estimated trade prices calculated?

13F filings disclose quarter-end holdings, not trade dates or execution prices. These estimates use each covered quarter's average market price; the add average excludes the opening position and quarters without price data. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.